| abstract |
The present invention provides androgen-independent prostate cancer cell lines, designated CL1, CL2, CL1-GFP, and CL2-GFP. The CL1 and CL2 sublines exhibit novel characteristics, including an unusually fast growth rate, are aggressively tumorigenic and metastatic (invasive) when injected in mice, and express different patterns of AR, PSA, and PSAM transcripts. Additionally, the present invention provides an animal prostate cancer model injected with the CL1 or CL2 subline. The present invention also provides screening assays involving the use of the CL-1 or CL-2 sublines for the discovery of agents that can inhibit proliferation or kill androgen independent prostate tumor cells. The present invention provides methods for delaying the progression of prostate cancer cells having the androgen-dependent phenotype to cells having the androgen-independent phenotype. |